Clinical Trial Update: Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating low-dose hormone replacement therapy with alendronate for osteoporosis and osteopenia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteopenia
• Osteoporosis

Drugs mentioned

• Low-Dose Hormone Replacement Therapy
• alendronate (alendronate)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Osteopenia, Osteoporosis | Phase 3 | Status: TERMINATED